Clinical Significance of Ndrg3 in Patients With Breast Cancer

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Clinical Significance of Ndrg3 in Patients With Breast Cancer Publisher Pubmed

Estiar MA¹ ; Zare AA² ; Esmaeili R³ ; Farahmand L³ ; Fazilaty H⁴ ; Jafari D⁵ ; Samadi T³ ; Majidzadeha K³

Source: Future Oncology Published:2017

Abstract

Aim: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients. Methods: Real-time quantitative PCR was performed. Results: NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3. Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others. Conclusion: We have presented that NDRG3 might be a tumor suppressor candidate. NDRG3 downregulation might be involved in the tumorigenesis and development of invasive BC in an advanced phase of the disease. © 2017 Future Medicine Ltd.

Related Docs

View other Related Docs

1. Expression of Erbb Gene Family in Females With Breast Cancer and Its Correlation With Clinicopathological Characteristics of the Disease, Molecular Biology Reports (2022)

2. Akap3 Correlates With Triple Negative Status and Disease Free Survival in Breast Cancer, BMC Cancer (2015)

3. Comparison of Brca1 Gene Expression and Ca15-3 Tumor Marker Level in Different Stages of Breast Cancer, Breast Journal (2024)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (3)

Reza Shirkoohi (2)

Other Related Docs

4. Investigation of Brcaness Associated Mirna-Gene Axes in Breast Cancer: Cell-Free Mir-182-5P As a Potential Expression Signature of Brcaness, BMC Cancer (2022)

5. The Reticulon-4 3-Bp Deletion/Insertion Polymorphism Is Associated With Structural Mrna Changes and the Risk of Breast Cancer: A Population-Based Case–Control Study With Bioinformatics Analysis, Life (2023)

6. Regulatory T Cells in Breast Cancer As a Potent Anti-Cancer Therapeutic Target, International Immunopharmacology (2020)

7. Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report From Cancer Institute of Iran, International Journal of Hematology-Oncology and Stem Cell Research (2017)

8. Gene Therapy: A Promising Approach for Breast Cancer Treatment, Cell Biochemistry and Function (2022)

9. Impact of Microrna Variants on Pi3k/Akt Signaling in Triple-Negative Breast Cancer: Comprehensive Review, Medical Oncology (2024)

10. Gene Panel Testing in Hereditary Breast Cancer, Archives of Iranian Medicine (2020)

11. Mir-483-3P Suppresses the Proliferation and Progression of Human Triple Negative Breast Cancer Cells by Targeting the Hdac8>Oncogene, Journal of Cellular Physiology (2020)

12. Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors, Biochemical Genetics (2023)

13. Spatial Analysis of Breast Cancer Incidence in Iran, Asian Pacific Journal of Cancer Prevention (2016)

14. Expression of Mirnas Targeting Mtor and S6k1 Genes of Mtor Signaling Pathway Including Mir-96, Mir-557, and Mir-3182 in Triple-Negative Breast Cancer, Applied Biochemistry and Biotechnology (2018)

15. Tumor Characteristics and Survival Rate of Her2-Low Breast Cancer Patients: A Retrospective Cohort Study, Scientific Reports (2023)

16. Neoadjuvant Chemotherapy in Patients With Her2-Negative Breast Cancer: A Report From Clinical Breast Cancer Registry of Iran, Archives of Iranian medicine (2024)

17. Circular Rna Hsa_Circ_0044234 As Distinct Molecular Signature of Triple Negative Breast Cancer: A Potential Regulator of Gata3, Cancer Cell International (2021)

18. Constructing Mrna, Mirna, Circrna and Lncrna Regulatory Network by Analysis of Microarray Data in Breast Cancer, Gene Reports (2022)

19. A Case Report of the Sustained and Rapid Response of Bevacizumab in a Tp53-Positive Breast Cancer and Liver Metastatic Patient Through Personalized Medicine, Frontiers in Oncology (2022)

20. The Expression Levels of Circulating Mir-129 and Mir-203A in Association With Breast Cancer and Related Metastasis, Iranian Journal of Public Health (2022)

Style	Citing Format
MLA	Estiar MA, et al.. "Clinical Significance of Ndrg3 in Patients With Breast Cancer." Future Oncology, vol. 13, no. 11, 2017, pp. 961-969.
APA	Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, Samadi T, Majidzadeha K (2017). Clinical Significance of Ndrg3 in Patients With Breast Cancer. Future Oncology, 13(11), 961-969.
Chicago	Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, Samadi T, Majidzadeha K. "Clinical Significance of Ndrg3 in Patients With Breast Cancer." Future Oncology 13, no. 11 (2017): 961-969.
Harvard	Estiar MA et al. (2017) 'Clinical Significance of Ndrg3 in Patients With Breast Cancer', Future Oncology, 13(11), pp. 961-969.
Vancouver	Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, et al.. Clinical Significance of Ndrg3 in Patients With Breast Cancer. Future Oncology. 2017;13(11):961-969.
BibTex	@article{ author = {Estiar MA and Zare AA and Esmaeili R and Farahmand L and Fazilaty H and Jafari D and Samadi T and Majidzadeha K}, title = {Clinical Significance of Ndrg3 in Patients With Breast Cancer}, journal = {Future Oncology}, volume = {13}, number = {11}, pages = {961-969}, year = {2017} }
RIS	TY - JOUR AU - Estiar MA AU - Zare AA AU - Esmaeili R AU - Farahmand L AU - Fazilaty H AU - Jafari D AU - Samadi T AU - Majidzadeha K TI - Clinical Significance of Ndrg3 in Patients With Breast Cancer JO - Future Oncology VL - 13 IS - 11 SP - 961 EP - 969 PY - 2017 ER -

Science Communicator Platform

Authors

Abstract